Although preclinical studies indicate that the GPR40 agonist LY2922470 mitigates acute brain injury [29], clinical investigations have revealed dose-limiting hepatotoxicity associated with GPR40-targeted therapies [30]. The gene discussed is FFAR1; the disease is injury.